, Société de pathologie infectieuse de langue française, 2009.
, Consensus conference on bacterial meningitis
, Med Mal Infect, vol.39, pp.175-186
, , p.374
, , p.375
, ESCMID Study Group for Infections of the Brain (ESGIB). 2016. ESCMID guideline: 376 diagnosis and treatment of acute bacterial meningitis, Clin Microbiol Infect, vol.22, pp.37-62
Practice guidelines for the management of bacterial meningitis, Clin Infect Dis, vol.379, pp.1267-1284, 2004. ,
, , vol.382
, Population pharmacokinetics of ceftriaxone and pharmacodynamic 383 considerations in haemodialysed patients, Clin Pharmacokinet, vol.45, pp.493-501, 2006.
Indications for a ceftriaxone dosing regimen in 385, 2011. ,
, Japanese paediatric patients using population pharmacokinetic/pharmacodynamic analysis 386 and simulation, J Pharm Pharmacol, vol.63, pp.65-72
The pharmacokinetics of ceftriaxone 388 based on population pharmacokinetics and the prediction of efficacy, 2009. ,
, Eur J Drug Metab Pharmacokinet, vol.34, pp.107-115
, , p.391
Population pharmacokinetics of ceftriaxone in critically ill septic 392 patients: a reappraisal, Br J Clin Pharmacol, vol.72, pp.758-767, 2011. ,
Comparison of the 394 probability of target attainment between ceftriaxone and cefepime in the cerebrospinal 395 fluid and serum against Streptococcus pneumoniae, Diagn Microbiol Infect Dis, vol.58, p.445, 2007. ,
High creatinine clearance in critically ill patients with community-acquired acute 399 infectious meningitis, BMC Nephrol, vol.398, p.124, 2012. ,
Bacterial meningitis. Rational selection and use of antibacterial 401 drugs, Drugs, vol.31, pp.266-278, 1986. ,
, , p.403
, , p.404
Tolerability of high-dose ceftriaxone in CNS infections: a 405 prospective multicentre cohort study, J Antimicrob Chemother, vol.74, pp.1078-1085 ,
, , p.407, 2011.
, Simultaneous determination of 12 beta-lactam antibiotics in human plasma by high-408 performance liquid chromatography with UV detection: application to therapeutic drug 409 monitoring, Antimicrob Agents Chemother, vol.55, pp.4873-4879
A method for 411 determining the free (unbound) concentration of ten beta-lactam antibiotics in human 412 plasma using high performance liquid chromatography with ultraviolet detection, J 413 Chromatogr B, vol.907, pp.178-184, 2012. ,
Accurate 415 detection of outliers and subpopulations with Pmetrics, a nonparametric and parametric 416 pharmacometric modeling and simulation package for R, Ther Drug Monit, vol.34, pp.467-476, 2012. ,
Prediction-corrected visual 418 predictive checks for diagnosing nonlinear mixed-effects models, AAPS J, vol.13, pp.143-151, 2011. ,
, , p.420
,
DALI: defining antibiotic levels in intensive care unit patients: are 422 current ?-lactam antibiotic doses sufficient for critically ill patients?, Clin Infect Dis, vol.423, pp.1072-1083, 2014. ,
Optimisation du traitement par 425 bêta-lactamines, 2018. ,
MIC and zone distributions and ECOFFs, 2019. ,
Effects of 430 concentration-dependent plasma protein binding on ceftriaxone kinetics, Clin Pharmacol 431 Ther, vol.29, pp.650-657, 1981. ,
, , p.433
Pharmacokinetics and pharmacodynamic target attainment of ceftriaxone 434 in adult severely ill sub-Saharan African patients: a population pharmacokinetic 435 modelling study, J Antimicrob Chemother, vol.73, pp.1620-1629, 2018. ,
, , p.437
Protein binding characteristics and pharmacokinetics of ceftriaxone in 438 intensive care unit patients, Br J Clin Pharmacol, vol.80, pp.525-533, 2015. ,
Clearance of ceftriaxone in 440 critical care patients with acute renal failure, Intensive Care Med, vol.16, pp.448-453, 1990. ,
, Population Pharmacokinetics, p.442, 2016.
, Fixed Dose Combination of Ceftriaxone and Sulbactam in Healthy and Infected Subjects
, AAPS PharmSciTech, vol.17, pp.1192-1203
The clinical relevance of plasma protein binding 445 changes, Clin Pharmacokinet, vol.52, pp.1-8, 2013. ,
, , p.447
Total and unbound ceftriaxone pharmacokinetics in critically 448 21, 2016. ,
, ill Australian Indigenous patients with severe sepsis, Int J Antimicrob Agents, vol.48, pp.748-449
Passage of 451 cefotaxime and ceftriaxone into cerebrospinal fluid of patients with uninflamed meninges, 1993. ,
, Antimicrob Agents Chemother, vol.37, pp.1518-1524
Ceftriaxone diffusion into cerebrospinal fluid of children with 454 meningitis, Antimicrob Agents Chemother, vol.23, pp.46-48, 1983. ,
Diffusion of ceftriaxone 456 into the cerebrospinal fluid of adults, J Antimicrob Chemother, vol.14, pp.427-430, 1984. ,
, , p.458
CSF concentration of ceftriaxone following high-dose 459 administration: pharmacological data from two French cohorts, J Antimicrob Chemother, 2019. ,
Bacterial meningitis--a view of the past 90 years, N Engl J Med, vol.461, pp.1826-1928, 2004. ,
Concentration-effect relationship of ceftazidime 463 explains why the time above the MIC is 40 percent for a static effect in vivo, Agents Chemother, vol.464, pp.3449-3451, 2007. ,
MIC-466 based dose adjustment: facts and fables, J Antimicrob Chemother, 2017. ,
, , 2007.
, Role of ceftazidime dose regimen on the selection of resistant Enterobacter cloacae in the 469 22 intestinal flora of rats treated for an experimental pulmonary infection, J Antimicrob, vol.470, pp.507-516
, Age (years), mean
, Weight (Kg), mean [SD; min, 1 st quartile, median, 3 rd quartile, max] 74.33 [16.6; 36.6, 62, 73, 85, 146] eGFR estimated by CKD-EPI (mL/min/1.73m 2 ), mean
, Daily ceftriaxone dosage (g), mean